Bader Abu Ghalyoun, MD
Cardiovascular Disease (Cardiology) · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Adventist Health Physicians Network · Lodi Memorial Hospital Association Inc
Looking this up.
Hospitals listed: Adventist Health Lodi Memorial · Dameron Hospital · St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ghalyoun’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C169074 · Current
Licensed to practise in California · since 2020 · expires 2028-06-30 · University of Jordan Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Lodi MemorialLodi, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.222, Oct 2024 – Sep 2025
- Dameron HospitalStockton, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 2 of 5 · 58% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — MRSA Bacteremia: 18.373, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Lodi Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 1 better, 3 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.222 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.16 to 2.22) · 678 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.59 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.28 (143.15 to 263.4) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 334 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 570 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,823 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 4,072 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 4,094 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.18 (0.83 to 5.53) · 476 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.8 to 4.13) · 448 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.29 (0 to 17.86) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 142 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0 to 1.53) · 3,347 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.368 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.655 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.506 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 450 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 47.3 · 381 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.2 · 604 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 661 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.6 (8.9 to 15.2) · 932 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 449 cases | No different | Jan 2024 – Dec 2024 |
What patients said (438 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Dameron Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 8 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| MRSA BacteremiaInfections | 18.373 | Worse | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.46 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.1 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.5 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.5 · 121 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 41 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.6 · 730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,121 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.52) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.06 (0.59 to 5.54) · 371 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 116 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.41 (0.76 to 4.05) · 363 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.35 (0.5 to 18.2) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.94 (0.72 to 9.16) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 74 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.37) · 1,066 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.678 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 118 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 144 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 41.3 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.5 · 89 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 22.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 178 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.2 · 44 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 78 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.2) · 386 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.5) · 261 cases | No different | Jan 2024 – Dec 2024 |
What patients said (385 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 1 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 72% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 74% |
| Patients who gave a rating of "9" or "10" (high) | 55% |
| Staff "always" explained new medications | 61% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 58% |
| Staff "always" explained possible side effects | 37% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$393,400
Medicare paid this office $393,400 for 1,790 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 319 | $74,404 | $144 |
| Critical care, first 30-74 minutes | 160 | $65,814 | $173 |
| Return visit (30+ min) | 358 | $41,115 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 245 | $38,108 | $148 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 69 | $25,045 | $363 |
See all 33 services
| Long return visit (40+ min) | 319 | $74,404 | $144 |
| Critical care, first 30-74 minutes | 160 | $65,814 | $173 |
| Return visit (30+ min) | 358 | $41,115 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 245 | $38,108 | $148 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 69 | $25,045 | $363 |
| Ultrasound of both sides of head and neck blood flow | 132 | $20,128 | $152 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 324 | $17,992 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $17,958 | $94 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 69 | $10,518 | $76 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 458 | $9,126 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 879 | $7,084 | $7 |
| New patient visit (45+ min) | 68 | $6,065 | $89 |
| New patient visit (60+ min) | 32 | $5,125 | $160 |
| Ultrasound of leg arteries or artery grafts | 27 | $5,086 | $188 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 69 | $3,809 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $3,700 | $64 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 15 | $2,894 | $193 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 473 | $2,784 | $5 |
| Programming of dual lead pacemaker system | 39 | $2,554 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,458 | $129 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $2,316 | $61 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 13 | $1,999 | $154 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,937 | $108 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 44 | $1,350 | $19 |
| Return visit (30+ min) | 11 | $1,296 | $81 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 33 | $1,268 | $24 |
| Injection, regadenoson, 0.1 mg | 48 | $1,216 | None |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 47 | $1,042 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 93 | $1,037 | $10 |
| Anticoagulant management of patient taking warfarin | 13 | $913 | $9 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $535 | $28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 45 | $269 | $6 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 23 | $238 | $10 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 1-10 | None |
| Leg revascularization (restoring blood flow) | 1-10 | None |
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
1,790 Original Medicare patients in 2024. Average age 76 · Under 65 10% · 85 and older 21% · Women 55% · Also on Medicaid 41% · Health risk score 1.99. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 44% · Heart failure 42% · Chronic kidney disease 40% · Coronary heart disease 39% · Atrial fibrillation 31% · COPD 26% · Depression 25% · Cancer 15% · Stroke 15% · Dementia 13%.
The office billed $1,436,163, Medicare allowed $523,228 and paid $393,400; for 6,036 services of 71 kinds; $1,216 of it was for drugs given in the office and $392,184 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,790 | 6,036 | 76 | 1.99 | $1,436,163 | $393,400 |
| 2023 | 919 | 3,904 | 74 | 1.83 | $1,273,259 | $350,052 |
| 2022 | 618 | 2,728 | 74 | 1.79 | $882,393 | $265,997 |
| 2021 | 432 | 2,011 | 74 | 1.85 | $748,985 | $206,365 |
| 2020 | 32 | 148 | 70 | 1.46 | $54,888 | $14,432 |
| 2019 | 28 | 28 | 80 | 2.11 | $17,129 | $4,377 |
| 2018 | 90 | 102 | 77 | 2.59 | $68,330 | $11,610 |
| 2017 | 25 | 27 | 78 | 1.78 | $20,766 | $3,379 |
| 2016 | 163 | 198 | 72 | 2.20 | $59,419 | $21,801 |
| 2015 | 555 | 1,361 | 71 | 2.52 | $215,019 | $102,637 |
| 2014 | 721 | 1,447 | 71 | 2.32 | $272,686 | $126,218 |
| 2013 | 628 | 1,582 | 70 | 2.46 | $263,867 | $121,681 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 29 services
| Long return visit (40+ min) | 248 | $51,578 | $135 |
| Return visit (30+ min) | 402 | $50,856 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 288 | $43,978 | $144 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 83 | $30,206 | $364 |
| Ultrasound of both sides of head and neck blood flow | 159 | $23,609 | $148 |
| Critical care, first 30-74 minutes | 54 | $21,215 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $20,397 | $94 |
| New patient visit (60+ min) | 96 | $15,203 | $158 |
| New patient visit (45+ min) | 109 | $13,186 | $121 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 83 | $12,554 | $76 |
| Injection, regadenoson, 0.1 mg | 50 | $8,841 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 154 | $8,445 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $8,293 | $138 |
| Ultrasound of leg arteries or artery grafts | 32 | $6,125 | $191 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 418 | $4,907 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 90 | $4,816 | $51 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 15 | $2,588 | $173 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 15 | $2,281 | $152 |
| Programming of dual lead pacemaker system | 18 | $1,466 | $64 |
| Anticoagulant management of patient taking warfarin | 17 | $897 | $9 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 166 | $884 | $5 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 28 | $813 | $15 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 13 | $792 | $61 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 19 | $666 | $19 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 29 | $554 | $15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $213 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 12 | $203 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 25 | $162 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $145 | $11 |
2022: 25 services
| Long return visit (40+ min) | 243 | $50,722 | $135 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 218 | $33,953 | $154 |
| Ultrasound of both sides of head and neck blood flow | 152 | $24,461 | $160 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 57 | $21,626 | $379 |
| Return visit (30+ min) | 202 | $21,021 | $90 |
| New patient visit (60+ min) | 95 | $16,480 | $173 |
| Critical care, first 30-74 minutes | 36 | $16,011 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $13,352 | $82 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 56 | $9,788 | $87 |
| Injection, regadenoson, 0.1 mg | 39 | $7,557 | None |
| New patient visit (45+ min) | 67 | $7,409 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,065 | $160 |
| Ultrasound of leg arteries or artery grafts | 25 | $4,990 | $200 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $3,636 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 59 | $3,122 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 249 | $3,005 | $10 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 14 | $2,429 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,369 | $55 |
| Programming of dual lead pacemaker system | 13 | $966 | $57 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $710 | $59 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 25 | $669 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 123 | $624 | $5 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 20 | $588 | $21 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $189 | $10 |
| Infusion, normal saline solution, 250 cc | 37 | $18 | None |
2021: 25 services
| Long return visit (40+ min) | 173 | $35,952 | $143 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 169 | $29,791 | $171 |
| Return visit (30+ min) | 174 | $22,782 | $103 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $22,608 | $411 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $10,002 | $84 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 54 | $9,777 | $89 |
| New patient visit (60+ min) | 58 | $9,748 | $168 |
| Critical care, first 30-74 minutes | 17 | $9,549 | $177 |
| Ultrasound of both sides of head and neck blood flow | 41 | $6,931 | $169 |
| New patient visit (45+ min) | 56 | $6,613 | $118 |
| Injection, regadenoson, 0.1 mg | 31 | $5,903 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,724 | $163 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 259 | $3,763 | $12 |
| Ultrasound of leg arteries or artery grafts | 17 | $3,708 | $218 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 52 | $2,774 | $53 |
| Ultrasound of leg arteries at rest and after exercise | 18 | $2,451 | $136 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 14 | $2,342 | $167 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 33 | $2,035 | $58 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 13 | $1,943 | $149 |
| Programming of dual lead pacemaker system | 18 | $1,199 | $67 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $763 | $64 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 20 | $547 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 17 | $525 | $25 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $173 | $10 |
| Infusion, normal saline solution, 250 cc | 56 | $32 | None |
2020: 3 services
| Long return visit (40+ min) | 11 | $2,201 | $122 |
| New patient visit (60+ min) | 14 | $1,545 | $110 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 24 | $359 | $14 |
2019: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,738 | $163 |
2018: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,657 | $161 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,283 | $80 |
2017: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,990 | $153 |
2016: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $8,989 | $147 |
| Initial hospital observation care per day, typically 70 minutes | 36 | $5,078 | $137 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,249 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,542 | $55 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,215 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,116 | $80 |
2015: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 226 | $27,851 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 141 | $22,756 | $80 |
| Hospital discharge day management, more than 30 minutes | 207 | $16,925 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $13,077 | $156 |
| Initial hospital observation care per day, typically 70 minutes | 39 | $5,558 | $143 |
| Hospital observation care on day of discharge | 59 | $3,365 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,636 | $105 |
| Critical care, first 30-74 minutes | 12 | $2,443 | $174 |
| Hospital discharge day management, 30 minutes or less | 32 | $1,773 | $55 |
| Follow-up observation care per day, typically 35 minutes | 16 | $1,535 | $81 |
| Follow-up observation care per day, typically 25 minutes | 24 | $1,464 | $54 |
| Initial hospital observation care per day, typically 50 minutes | 11 | $1,069 | $97 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $660 | $30 |
2014: 12 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 234 | $36,041 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 163 | $25,612 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 221 | $21,769 | $54 |
| Hospital discharge day management, more than 30 minutes | 203 | $16,034 | $78 |
| Initial hospital observation care per day, typically 70 minutes | 60 | $8,383 | $137 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $5,506 | $102 |
| Critical care, first 30-74 minutes | 23 | $5,322 | $172 |
| Hospital observation care on day of discharge | 38 | $2,028 | $53 |
| Initial hospital observation care per day, typically 50 minutes | 14 | $1,381 | $99 |
| Hospital discharge day management, 30 minutes or less | 18 | $923 | $51 |
| Follow-up observation care per day, typically 25 minutes | 14 | $767 | $51 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $508 | $30 |
2013: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 263 | $29,804 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 154 | $26,038 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 146 | $21,688 | $146 |
| Hospital discharge day management, more than 30 minutes | 232 | $18,389 | $77 |
| Critical care, first 30-74 minutes | 33 | $8,306 | $166 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 55 | $5,496 | $100 |
| Initial hospital observation care per day, typically 70 minutes | 34 | $4,507 | $133 |
| Hospital discharge day management, 30 minutes or less | 30 | $1,580 | $53 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,515 | $76 |
| Hospital observation care on day of discharge | 19 | $951 | $50 |
| Follow-up observation care per day, typically 25 minutes | 12 | $851 | $50 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $810 | $29 |
Medicaid work
$204,961 in 2024
Medicaid paid $204,961 for 4,226 billed services this clinician did in 2024, up to 203 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 557 | $83,581 |
| Long return visit (40+ min) | 383 | $22,706 |
| Return visit (30+ min) | 513 | $22,312 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,347 | $15,544 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 31 | $12,576 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 549 | $9,667 |
| CARDIOVASCULAR STRESS TEST | 64 | $7,333 |
| Face-to-face behavioral counseling for obesity, 15 minutes | 303 | $7,261 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 29 | $6,957 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 55 | $5,806 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 171 | $4,957 |
| New patient visit (45+ min) | 59 | $4,415 |
| 2024 | 4,226 | 17 | 203 | $204,961 |
| 2023 | 4,239 | 19 | 96 | $327,201 |
| 2022 | 2,029 | 11 | 67 | $223,013 |
| 2021 | 2,317 | 12 | 76 | $248,940 |
| 2020 | 168 | 8 | 42 | $20,933 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 607 | $114,009 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 140 | $44,203 |
| Return visit (30+ min) | 772 | $31,605 |
| Long return visit (40+ min) | 456 | $26,315 |
| CARDIOVASCULAR STRESS TEST | 202 | $21,822 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 753 | $21,168 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 97 | $20,215 |
| New patient visit (45+ min) | 233 | $19,016 |
| New patient visit (60+ min) | 106 | $8,600 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 39 | $6,635 |
| Injection, regadenoson, 0.1 mg | 15 | $4,118 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 219 | $3,441 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 375 | $95,147 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 74 | $30,222 |
| Long return visit (40+ min) | 337 | $20,570 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 67 | $16,486 |
| Return visit (30+ min) | 328 | $15,497 |
| CARDIOVASCULAR STRESS TEST | 120 | $14,997 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 432 | $14,387 |
| New patient visit (45+ min) | 103 | $8,991 |
| New patient visit (60+ min) | 51 | $4,261 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 129 | $2,431 |
| Infusion, normal saline solution, 250 cc | 13 | $24 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 391 | $96,537 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 77 | $27,849 |
| Long return visit (40+ min) | 336 | $23,780 |
| Return visit (30+ min) | 391 | $19,962 |
| CARDIOVASCULAR STRESS TEST | 158 | $19,163 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 551 | $18,853 |
| New patient visit (45+ min) | 159 | $15,683 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 64 | $12,738 |
| New patient visit (60+ min) | 98 | $10,721 |
| Injection, regadenoson, 0.1 mg | 13 | $2,740 |
| Short return visit (20+ min) | 15 | $573 |
| Infusion, normal saline solution, 250 cc | 64 | $339 |
2020
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 12 | $6,266 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $4,080 |
| New patient visit (60+ min) | 28 | $3,397 |
| CARDIOVASCULAR STRESS TEST | 15 | $2,158 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 57 | $2,154 |
| New patient visit (45+ min) | 14 | $1,137 |
| Return visit (30+ min) | 16 | $883 |
| Long return visit (40+ min) | 12 | $858 |
Drugs they prescribed that Part D paid
$2,056,500
Pharmacies billed $2,056,500 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 9,604) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
7,448 generic and 2,156 brand-name prescriptions · $2,056,500 in drug cost · 13 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Entresto | 710 | $675,203 | $951 |
| Eliquis | 329 | $344,107 | $1,046 |
| Xarelto | 305 | $310,498 | $1,018 |
| Jardiance | 323 | $302,881 | $938 |
| Farxiga | 139 | $114,651 | $825 |
See all 60 drugs
| Entresto | 710 | $675,203 | $951 |
| Eliquis | 329 | $344,107 | $1,046 |
| Xarelto | 305 | $310,498 | $1,018 |
| Jardiance | 323 | $302,881 | $938 |
| Farxiga | 139 | $114,651 | $825 |
| Repatha Sureclick | 67 | $60,644 | $905 |
| Multaq | 15 | $29,028 | $1,935 |
| Brilinta | 33 | $17,180 | $521 |
| Dapagliflozin | 22 | $16,999 | $773 |
| Atorvastatin | 861 | $9,654 | $11 |
| Praluent | 18 | $9,456 | $525 |
| Carvedilol | 1,056 | $9,305 | $9 |
| Metoprolol | 571 | $8,084 | $14 |
| Amiodarone | 63 | $7,473 | $119 |
| Rosuvastatin | 335 | $7,211 | $22 |
| Icosapent Ethyl | 11 | $6,163 | $560 |
| Valsartan | 94 | $4,140 | $44 |
| Cilostazol | 175 | $4,124 | $24 |
| Hydralazine | 295 | $3,958 | $13 |
| Amlodipine Besylate | 664 | $3,940 | $6 |
| Losartan | 442 | $3,935 | $9 |
| Furosemide | 515 | $3,175 | $6 |
| Midodrine | 58 | $3,160 | $54 |
| Clopidogrel | 212 | $2,990 | $14 |
| Isosorbide Mononitrate Er | 196 | $2,839 | $14 |
| Metoprolol | 306 | $2,288 | $7 |
| Lisinopril | 308 | $2,030 | $7 |
| Metolazone | 27 | $1,862 | $69 |
| Ranolazine Er | 20 | $1,780 | $89 |
| Diltiazem 24hr Er (Cd) | 50 | $1,662 | $33 |
| Ezetimibe | 37 | $1,518 | $41 |
| Fenofibrate | 19 | $1,241 | $65 |
| Torsemide | 38 | $1,045 | $27 |
| Digoxin | 44 | $1,017 | $23 |
| Losartan-Hydrochlorothiazide | 40 | $968 | $24 |
| Warfarin | 40 | $957 | $24 |
| Chlorthalidone | 49 | $945 | $19 |
| Pravastatin | 43 | $884 | $21 |
| Spironolactone | 103 | $838 | $8 |
| Potassium Chloride | 42 | $826 | $20 |
| Albuterol Sulfate Hfa | 16 | $687 | $43 |
| Pantoprazole | 46 | $594 | $13 |
| Benazepril | 59 | $583 | $10 |
| Gabapentin | 47 | $578 | $12 |
| Flecainide Acetate | 18 | $505 | $28 |
| Nitroglycerin | 41 | $503 | $12 |
| Lisinopril-Hydrochlorothiazide | 26 | $349 | $13 |
| Simvastatin | 40 | $340 | $8 |
| Scopolamine | 12 | $334 | $28 |
| Bumetanide | 13 | $312 | $24 |
| Hydrochlorothiazide | 88 | $306 | $3 |
| Sotalol | 21 | $304 | $14 |
| Levothyroxine | 24 | $284 | $12 |
| Ramipril | 14 | $283 | $20 |
| Diltiazem | 13 | $246 | $19 |
| Clonidine | 32 | $226 | $7 |
| Meclizine | 15 | $161 | $11 |
| Fludrocortisone Acetate | 15 | $135 | $9 |
| Niacin Er | 11 | $117 | $11 |
| Omeprazole | 11 | $76 | $7 |
Year by year
| 2024 | 9,604 | 1,098 | 0% (0) | 22% | $2,056,500 |
| 2023 | 7,348 | 919 | None | None | $1,334,112 |
| 2022 | 3,977 | 623 | None | 14% | $472,915 |
| 2021 | 2,029 | 381 | None | 13% | $167,510 |
| 2020 | 88 | 20 | 0% (0) | 25% | $7,290 |
| 2019 | 41 | None | 0% (0) | 0% | $138 |
| 2016 | 24 | None | None | None | $1,548 |
| 2015 | 326 | 135 | 9% (28) | None | $12,274 |
| 2014 | 275 | 120 | 8% (22) | None | $15,452 |
| 2013 | 355 | 143 | 9% (30) | None | $27,271 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 56 drugs
| Entresto | 425 | $401,506 | $945 |
| Xarelto | 276 | $245,279 | $889 |
| Eliquis | 193 | $210,345 | $1,090 |
| Jardiance | 173 | $152,978 | $884 |
| Farxiga | 125 | $107,430 | $859 |
| Repatha Sureclick | 24 | $20,659 | $861 |
| Atorvastatin | 852 | $16,559 | $19 |
| Brilinta | 21 | $13,173 | $627 |
| Carvedilol | 737 | $11,569 | $16 |
| Metoprolol | 507 | $9,969 | $20 |
| Rosuvastatin | 175 | $8,631 | $49 |
| Amlodipine Besylate | 569 | $7,622 | $13 |
| Losartan | 349 | $5,698 | $16 |
| Cilostazol | 167 | $5,531 | $33 |
| Hydralazine | 173 | $4,788 | $28 |
| Isosorbide Mononitrate Er | 197 | $4,725 | $24 |
| Furosemide | 423 | $4,025 | $10 |
| Lisinopril | 269 | $3,833 | $14 |
| Midodrine | 67 | $3,389 | $51 |
| Ranolazine Er | 20 | $2,934 | $147 |
| Metoprolol | 239 | $2,873 | $12 |
| Clopidogrel | 162 | $2,676 | $17 |
| Chlorthalidone | 58 | $2,475 | $43 |
| Ezetimibe | 27 | $2,293 | $85 |
| Amiodarone | 32 | $1,923 | $60 |
| Metolazone | 22 | $1,757 | $80 |
| Valsartan | 51 | $1,723 | $34 |
| Isosorbide Dinitrate | 15 | $1,599 | $107 |
| Pravastatin | 53 | $1,450 | $27 |
| Losartan-Hydrochlorothiazide | 33 | $1,329 | $40 |
| Bumetanide | 17 | $1,151 | $68 |
| Diltiazem 24hr Er (Cd) | 24 | $1,109 | $46 |
| Ventolin Hfa | 16 | $983 | $61 |
| Spironolactone | 55 | $966 | $18 |
| Simvastatin | 46 | $956 | $21 |
| Digoxin | 27 | $945 | $35 |
| Warfarin | 33 | $935 | $28 |
| Pantoprazole | 37 | $841 | $23 |
| Torsemide | 31 | $808 | $26 |
| Albuterol Sulfate Hfa | 21 | $741 | $35 |
| Gabapentin | 38 | $700 | $18 |
| Nitroglycerin | 34 | $690 | $20 |
| Lisinopril-Hydrochlorothiazide | 18 | $622 | $35 |
| Propranolol | 16 | $611 | $38 |
| Sildenafil Citrate | 11 | $445 | $40 |
| Nifedipine Er | 18 | $445 | $25 |
| Fenofibrate | 14 | $443 | $32 |
| Clonidine | 23 | $436 | $19 |
| Benazepril | 30 | $388 | $13 |
| Hydrochlorothiazide | 66 | $336 | $5 |
| Potassium Chloride | 11 | $314 | $29 |
| Fludrocortisone Acetate | 14 | $313 | $22 |
| Niacin Er | 13 | $307 | $24 |
| Levothyroxine | 21 | $290 | $14 |
| Sotalol | 16 | $285 | $18 |
| Omeprazole | 14 | $180 | $13 |
2022: 39 drugs
| Eliquis | 188 | $170,488 | $907 |
| Entresto | 99 | $86,434 | $873 |
| Xarelto | 66 | $65,983 | $1,000 |
| Jardiance | 51 | $42,421 | $832 |
| Atorvastatin | 518 | $7,209 | $14 |
| Metoprolol | 332 | $5,790 | $17 |
| Carvedilol | 396 | $4,936 | $12 |
| Isosorbide Dinitrate | 17 | $4,537 | $267 |
| Rosuvastatin | 101 | $3,989 | $39 |
| Losartan | 254 | $3,194 | $13 |
| Ranolazine Er | 13 | $2,871 | $221 |
| Midodrine | 19 | $2,542 | $134 |
| Amiodarone | 19 | $2,517 | $132 |
| Amlodipine Besylate | 259 | $2,410 | $9 |
| Isosorbide Mononitrate Er | 126 | $2,296 | $18 |
| Cilostazol | 56 | $2,122 | $38 |
| Lisinopril | 233 | $2,073 | $9 |
| Furosemide | 318 | $2,002 | $6 |
| Metolazone | 20 | $1,645 | $82 |
| Clopidogrel | 84 | $1,555 | $19 |
| Hydralazine | 63 | $1,247 | $20 |
| Chlorthalidone | 29 | $1,139 | $39 |
| Losartan-Hydrochlorothiazide | 29 | $1,063 | $37 |
| Metoprolol | 104 | $823 | $8 |
| Nitroglycerin | 28 | $779 | $28 |
| Potassium Chloride | 14 | $652 | $47 |
| Pravastatin | 29 | $624 | $22 |
| Albuterol Sulfate Hfa | 12 | $603 | $50 |
| Lisinopril-Hydrochlorothiazide | 19 | $453 | $24 |
| Bumetanide | 11 | $355 | $32 |
| Spironolactone-Hctz | 11 | $306 | $28 |
| Spironolactone | 32 | $279 | $9 |
| Hydrochlorothiazide | 76 | $234 | $3 |
| Warfarin | 19 | $205 | $11 |
| Levothyroxine | 12 | $193 | $16 |
| Benazepril | 23 | $137 | $6 |
| Simvastatin | 25 | $110 | $4 |
| Meclizine | 12 | $88 | $7 |
| Pantoprazole | 12 | $61 | $5 |
2021: 22 drugs
| Eliquis | 82 | $62,527 | $763 |
| Xarelto | 49 | $39,118 | $798 |
| Entresto | 30 | $20,747 | $692 |
| Atorvastatin | 273 | $3,639 | $13 |
| Metoprolol | 142 | $2,801 | $20 |
| Carvedilol | 263 | $2,787 | $11 |
| Rosuvastatin | 54 | $1,973 | $37 |
| Losartan | 99 | $1,108 | $11 |
| Lisinopril | 174 | $1,064 | $6 |
| Furosemide | 153 | $936 | $6 |
| Amlodipine Besylate | 106 | $852 | $8 |
| Isosorbide Mononitrate Er | 60 | $827 | $14 |
| Clopidogrel | 51 | $639 | $13 |
| Metoprolol | 75 | $374 | $5 |
| Losartan-Hydrochlorothiazide | 12 | $300 | $25 |
| Hydrochlorothiazide | 80 | $283 | $4 |
| Amiodarone | 12 | $275 | $23 |
| Pravastatin | 21 | $247 | $12 |
| Lisinopril-Hydrochlorothiazide | 23 | $202 | $9 |
| Hydralazine | 21 | $183 | $9 |
| Spironolactone | 21 | $127 | $6 |
| Benazepril | 12 | $118 | $10 |
2020: 1 drug
| Lisinopril | 12 | $59 | $5 |
2015: 7 drugs
| Cefdinir | 12 | $345 | $29 |
| Levofloxacin | 20 | $199 | $10 |
| Hydrocodone-Acetaminophen | 15 | $142 | $9 |
| Pantoprazole | 14 | $121 | $9 |
| Prednisone | 18 | $92 | $5 |
| Metoprolol | 15 | $49 | $3 |
| Furosemide | 12 | $41 | $3 |
2014: 5 drugs
| Levofloxacin | 18 | $159 | $9 |
| Pantoprazole | 14 | $123 | $9 |
| Hydrocodone-Acetaminophen | 16 | $104 | $6 |
| Prednisone | 18 | $91 | $5 |
| Metoprolol | 12 | $46 | $4 |
2013: 5 drugs
| Levofloxacin | 26 | $338 | $13 |
| Pantoprazole | 13 | $200 | $15 |
| Hydrocodone-Acetaminophen | 16 | $108 | $7 |
| Prednisone | 23 | $84 | $4 |
| Lisinopril | 11 | $52 | $5 |
Money from drug and device companies
$1,914 in 2025
| 2025 | 13 | 49 | $200 | $1,914 |
| 2024 | 17 | 70 | None | $1,705 |
| 2023 | 17 | 81 | None | $4,003 |
| 2022 | 15 | 46 | None | $904 |
| 2021 | 9 | 18 | None | $982 |
| 2020 | 4 | 4 | None | $1,176 |
| 2019 | 2 | 3 | None | $175 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Azure Xt Dr Mri Surescan | $670 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $300 | 6 payments
|
| Novartis Pharmaceuticals | Leqvio | $282 | 15 payments
|
| Abiomed | None | $104 | 1 payment
|
| Pfizer | Eliquis | $95 | 4 payments
|
| Philips North America | Ambulatory Monitoring & Diagnostics Undivided | $82 | 3 payments
|
See all 49 published payments
| Medtronic | Meals · 2025-12-16 | Symplicity G3 | $15 |
| Pfizer | Meals · 2025-12-03 | Eliquis | $29 |
| Novartis Pharmaceuticals | Meals · 2025-11-13 | Leqvio | $18 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Leqvio | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-14 | Kerendia | $22 |
| Abiomed | Meals · 2025-10-02 | None | $104 |
| Novartis Pharmaceuticals | Meals · 2025-10-02 | Leqvio | $24 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | Leqvio | $23 |
| Bayer Healthcare Pharmaceuticals | Consulting · 2025-09-30 | Adempas | $200 |
| Merck Sharp & Dohme | Meals · 2025-09-18 | Verquvo | $16 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Leqvio | $19 |
| Bayer Healthcare Pharmaceuticals | Education · 2025-09-08 | Kerendia | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-08 | Kerendia | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-06 | Farxiga | $19 |
| Merck Sharp & Dohme | Meals · 2025-08-20 | Verquvo | $19 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Leqvio | $11 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Leqvio | $11 |
| Philips North America | Meals · 2025-08-12 | Ambulatory Monitoring & Diagnostics Undivided | $33 |
| Novartis Pharmaceuticals | Meals · 2025-07-09 | Leqvio | $20 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-01 | Lifevest | $19 |
| Pfizer | Meals · 2025-06-23 | Eliquis | $29 |
| Medtronic | Travel · 2025-06-21 | None | $120 |
| Medtronic | Meals · 2025-06-20 | Azure Xt Dr Mri Surescan | $140 |
| Medtronic | Travel · 2025-06-09 | None | $395 |
| Philips North America | Meals · 2025-06-03 | Ambulatory Monitoring & Diagnostics Undivided | $26 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-20 | Kerendia | $15 |
| Novartis Pharmaceuticals | Meals · 2025-05-15 | Leqvio | $30 |
| Novartis Pharmaceuticals | Meals · 2025-05-13 | Leqvio | $10 |
| Lilly USA | Meals · 2025-05-01 | Zepbound | $27 |
| Novartis Pharmaceuticals | Meals · 2025-04-16 | Leqvio | $19 |
| Novo Nordisk | Meals · 2025-04-10 | Wegovy | $81 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-10 | Farxiga | $19 |
| Actelion Pharmaceuticals US | Meals · 2025-04-07 | Opsumit | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-20 | Farxiga | $19 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-03-18 | Lifevest | $14 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Leqvio | $23 |
| Pfizer | Meals · 2025-03-12 | Eliquis | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-11 | Jardiance | $20 |
| Novartis Pharmaceuticals | Meals · 2025-03-06 | Leqvio | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-03 | Farxiga | $17 |
| Pfizer | Meals · 2025-02-22 | Eliquis | $17 |
| Merck Sharp & Dohme | Meals · 2025-02-10 | Verquvo | $29 |
| Lilly USA | Meals · 2025-02-06 | Zepbound | $20 |
| Philips North America | Meals · 2025-02-03 | Mcot | $24 |
| Merck Sharp & Dohme | Meals · 2025-01-28 | Verquvo | $17 |
| Novartis Pharmaceuticals | Meals · 2025-01-27 | Leqvio | $19 |
| Novartis Pharmaceuticals | Meals · 2025-01-23 | Leqvio | $16 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-21 | Jardiance | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-09 | Kerendia | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,705
| Abiomed | Impella | $334 | 6 payments
|
| Novo Nordisk | Ozempic | $310 | 11 payments
|
| Novartis Pharmaceuticals | Leqvio | $231 | 13 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $137 | 7 payments
|
| Janssen Pharmaceuticals | Xarelto | $102 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $83 | 4 payments
|
| Merck Sharp & Dohme | Verquvo | $71 | 4 payments
|
| Philips North America | (5044) Mcot | $68 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $64 | 3 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $61 | 2 payments
|
| Pfizer | Eliquis | $55 | 2 payments
|
| Lexicon Pharmaceuticals | None | $45 | 3 payments
|
| Amgen | Repatha | $41 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $38 | 2 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $27 | 1 payment
|
| Abbott Laboratories | Mitraclip | $25 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $13 | 1 payment
|
2023: $4,003
| Medtronic | Advisa Dr Mri Surescan | $2,856 | 22 payments
|
| Novartis Pharmaceuticals | Leqvio | $203 | 11 payments
|
| Janssen Pharmaceuticals | Xarelto | $186 | 9 payments
|
| Novo Nordisk | Wegovy | $140 | 8 payments
|
| Amgen | Repatha | $117 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $84 | 4 payments
|
| Impulse Dynamics (USA) | Optimizer | $82 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $72 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $63 | 4 payments
|
| Tactile Systems Technology | Flexitouch Plus | $47 | 3 payments
|
| Lexicon Pharmaceuticals | Inpefa | $37 | 2 payments
|
| Chiesi USA | Cleviprex | $26 | 1 payment
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $20 | 1 payment
|
| Cook Medical | Zilver Ptx | $19 | 1 payment
|
| Cardiovascular Systems | Diamondback Peripheral | $19 | 1 payment
|
| Philips Electronics North America | (5044) Mcot | $17 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $13 | 1 payment
|
2022: $904
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $141 | 8 payments
|
| Novartis Pharmaceuticals | Entresto | $139 | 8 payments
|
| Sanofi-Aventis U.S. | Multaq | $92 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $88 | 4 payments
|
| Merck Sharp & Dohme | Verquvo | $86 | 4 payments
|
| Abbott Laboratories | Assurity | $84 | 2 payments
|
| Amgen | Repatha | $53 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $51 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Verquvo | $42 | 3 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $36 | 1 payment
|
| Resmed | Air 11 | $25 | 1 payment
|
| Boston Scientific | Watchman Access System | $20 | 1 payment
|
| Medtronic | Reveal Linq | $18 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $13 | 1 payment
|
2021: $982
| Abbott Laboratories | Assurity Pacemaker | $731 | 5 payments
|
| Amgen | Repatha | $54 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $44 | 2 payments
|
| Kiniksa Pharmaceuticals | None | $44 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $41 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $22 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $17 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $16 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $14 | 1 payment
|
2020: $1,176
| Boston Scientific | General - Structural Heart | $1,105 | 1 payment
|
| Asahi Intecc USA | Asahi Ptca Guide Wire | $41 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $15 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $15 | 1 payment
|
2019: $175
| Acist Medical Systems | Hd-Ivus | $147 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $28 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1740492214
- Licence
- CA C169074, WV 24179California C169074: Current · expires 2028-06-30
- Group
- Adventist Health Physicians Network · Lodi Memorial Hospital Association Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Internal medicine (207R00000X); Hospitalist (208M00000X)
- Mailing address
- 1801 E March Ln Ste D400, Stockton, CA, 95210
- NPI first listed
- 2007-05-04
- NPI last updated
- 2020-06-25
- NPI record certified
- 2020-06-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3200 Maccorkle Ave Se, Charleston, WV, 25304